Get started
Exelixis, Inc.Exelixis, Inc.Exelixis, Inc.

Exelixis, Inc.

No trades
See on Supercharts
OverviewFinancialsNewsIdeasDiscussionsForecastSeasonalsETFs

EX9 chart


Full chart

EX9 upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪9.21 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
19.54
Basic EPS (TTM)
1.83 EUR
Net income (FY)
‪503.53 M‬ EUR
Revenue (FY)
‪2.09 B‬ EUR
Shares float
‪260.65 M‬
Beta (1Y)
1.19

Employees


Employees (FY)
‪1.15 K‬
Change (1Y)
−163 −12.44%
Revenue / Employee (1Y)
—
Net income / Employee (1Y)
—

About Exelixis, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Michael M. Morrissey
Website
exelixis.com
Headquarters
Alameda
Founded
1994
ISIN
US30161Q1040
FIGI
BBG000BL32G5
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Check out other big names from the same industry as EX9.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

EX9 news



Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs with EX9 exposure


IJH
iShares Core S&P Mid-Cap ETF
Weight
0.35%
Market value
‪355.79 M‬
USD
VTI
Vanguard Total Stock Market ETF
Weight
0.02%
Market value
‪305.15 M‬
USD
VB
Vanguard Small-Cap ETF
Weight
0.14%
Market value
‪235.81 M‬
USD
VBK
Vanguard Small-Cap Growth ETF
Weight
0.34%
Market value
‪131.65 M‬
USD
XBI
SPDR S&P BIOTECH ETF
Weight
1.95%
Market value
‪119.50 M‬
USD
VXF
Vanguard Extended Market ETF
Weight
0.13%
Market value
‪109.44 M‬
USD
XMHQ
Invesco S&P MidCap Quality ETF
Weight
2.00%
Market value
‪105.36 M‬
USD
MDY
SPDR S&P Midcap 400 ETF Trust
Weight
0.35%
Market value
‪83.50 M‬
USD
IBB
iShares Biotechnology ETF
Weight
1.03%
Market value
‪63.72 M‬
USD
IJK
iShares S&P Mid-Cap 400 Growth ETF
Weight
0.67%
Market value
‪61.23 M‬
USD
IWP
iShares Russell Mid-Cap Growth ETF
Weight
0.28%
Market value
‪59.16 M‬
USD

Explore more ETFs 

Sparks


Curated watchlists where EX9 is featured.

See all sparks 

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange Exelixis, Inc. stocks are traded under the ticker EX9.
We've gathered analysts' opinions on Exelixis, Inc. future price: according to them, EX9 price has a max estimate of 51.08 EUR and a min estimate of 29.80 EUR. Watch EX9 chart and read a more detailed Exelixis, Inc. stock forecast: see what analysts think of Exelixis, Inc. and suggest that you do with its stocks.
EX9 reached its all-time high on Jun 23, 2025 with the price of 44.40 EUR, and its all-time low was 1.03 EUR and was reached on Dec 17, 2014. View more price dynamics on EX9 chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track Exelixis, Inc. financials in yearly and quarterly reports right on TradingView.
Exelixis, Inc. is going to release the next earnings report on Nov 4, 2025. Keep track of upcoming events with our Earnings Calendar.
EX9 earnings for the last quarter are 0.64 EUR per share, whereas the estimation was 0.57 EUR resulting in a 12.31% surprise. The estimated earnings for the next quarter are 0.58 EUR per share. See more details about Exelixis, Inc. earnings.
Exelixis, Inc. revenue for the last quarter amounts to ‪482.40 M‬ EUR, despite the estimated figure of ‪489.98 M‬ EUR. In the next quarter, revenue is expected to reach ‪502.30 M‬ EUR.
EX9 net income for the last quarter is ‪156.92 M‬ EUR, while the quarter before that showed ‪147.54 M‬ EUR of net income which accounts for 6.36% change. Track more Exelixis, Inc. financial stats to get the full picture.
No, EX9 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 5, 2025, the company has ‪1.15 K‬ employees. See our rating of the largest employees — is Exelixis, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Exelixis, Inc. EBITDA is ‪663.44 M‬ EUR, and current EBITDA margin is 33.14%. See more stats in Exelixis, Inc. financial statements.
Like other stocks, EX9 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Exelixis, Inc. stock right from TradingView charts — choose your broker and connect to your account.